Research Publications

Oncology

GBR 1302

GBR 1302: Effect of CD3-HER2, a bispecific T-cell engager antibody, in Trastuzumab-resistant cancers

Event : 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO)

View

Oncology

GBR 1302 and GBR 1342

Dr. Venkateshwar Reddy, Vice President and Global head of Translational Sciences, Glenmark Pharmaceuticals, speaks to HemOnc Today about the company’s bispecific T-cell engager platform and its promise in the overall clinical setting for both solid and hematology tumors

Event : 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO)

View

Oncology

GBR 1342

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Event : 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO)

View

Oncology

GBR 1302

Dual targeting of CD3 and HER2 using GBR 1302, a BEAT® antibody, leads to potent killing of HER2 overexpressing target cells

Event : Keystone Symposia on Molecular and Cell Biology 2015

View

Oncology

GBR 1302

GBR1302-BEAT®bispecificantibody for the treatment of HER2 positive cancers

Event : PEGS 2014

View

Oncology

GBR 1302

Upstream process development for GBR 1302, a Bispecific Antibody Based on Glenmark's Proprietary BEAT® (Bispecific Engagement By Antibodies Based on T Cell Receptor) Format

Event : ESCAT 2015

View

Pain

GRC 27864

Novel, selective & orally active Microsomal Prostaglandin E Synthase-1 Inhibitor for potential treatment of Arthritic Pain

Event : Inflammation Research Association - 17th International Conference

View

Pain

GRC 27864

GRC 27864 - A novel, selective & orally active Microsomal Prostaglandin E Synthase 1 (mPGES-1) inhibitor for potential treatment of arthritic pain

Event : World Pharma congress, May 21-23, 2014

View

DERMATOLOGY

GBR 830

GBR 830: An antagonistic anti-human OX40 mAb with potent suppressive effect on pathological immune responses

Event : PEGS 2014

View